Table 1.

Patient characteristics


Patient no.

Age, y

Sex

Ig type

Therapeutic history

13q status by FISH
1   66   M   IgG,λ   ID, IEV, Hd-Mel   ND  
2   66   M   IgG,κ   VAD   Del  
3   45   F   κ   VAD, IEV, Hd-Mel   Del  
4   57   F   NS   VAD, IEV, Hd-Mel   Del  
5   61   M   IgG,λ   D, IEV, Hd-Mel   Nor  
6   58   F   IgG,κ   VAD, IEV, Hd-Mel   Del  
7   70   M   IgG,λ   D, IEV, T-Hd-Mel   ND  
8   63   F   IgG,κ   VAD, AD   Nor  
9   42   M   IgG,κ   ID, IEV, Hd-Mel   Nor  
10   61   M   IgG   ID, Mel, VCAP, BP, Bort   ND  
11   41   F   IgG,λ   VAD   Nor  
12   68   M   IgG,κ   MP, B, D, VAD   ND  
13   66   M   IgG,κ   MP, VAD, CC5013 + D   ND  
14   65   F   IgG   MP, Thal + D   ND  
15   61   M   κ   Untreated   ND  
16   53   F   IgG,λ   VAD   Del  
17   81   F   IgG,λ   Untreated   ND  
18   64   M   IgG,κ   ID, IEV, T-Hd-Mel, TamD   ND  
19   74   M   IgG,κ   MP, D, Thal   ND  
20   68   M   NS   D, VAD, D, Hd-Mel   ND  
21   60   M   IgG,λ   VAD, IEV, Hd-Mel   Nor  
22   59   F   IgG,λ   VAD, IEV, Hd-Mel   ND  
23   65   M   IgG,κ   D   ND  
24   59   M   IgG,κ   MP, VBAP, CC5013 + D   ND  
25
 
65
 
F
 
IgG,κ
 
VAD, IEV, T-Hd-Mel, D, Bort
 
ND
 

Patient no.

Age, y

Sex

Ig type

Therapeutic history

13q status by FISH
1   66   M   IgG,λ   ID, IEV, Hd-Mel   ND  
2   66   M   IgG,κ   VAD   Del  
3   45   F   κ   VAD, IEV, Hd-Mel   Del  
4   57   F   NS   VAD, IEV, Hd-Mel   Del  
5   61   M   IgG,λ   D, IEV, Hd-Mel   Nor  
6   58   F   IgG,κ   VAD, IEV, Hd-Mel   Del  
7   70   M   IgG,λ   D, IEV, T-Hd-Mel   ND  
8   63   F   IgG,κ   VAD, AD   Nor  
9   42   M   IgG,κ   ID, IEV, Hd-Mel   Nor  
10   61   M   IgG   ID, Mel, VCAP, BP, Bort   ND  
11   41   F   IgG,λ   VAD   Nor  
12   68   M   IgG,κ   MP, B, D, VAD   ND  
13   66   M   IgG,κ   MP, VAD, CC5013 + D   ND  
14   65   F   IgG   MP, Thal + D   ND  
15   61   M   κ   Untreated   ND  
16   53   F   IgG,λ   VAD   Del  
17   81   F   IgG,λ   Untreated   ND  
18   64   M   IgG,κ   ID, IEV, T-Hd-Mel, TamD   ND  
19   74   M   IgG,κ   MP, D, Thal   ND  
20   68   M   NS   D, VAD, D, Hd-Mel   ND  
21   60   M   IgG,λ   VAD, IEV, Hd-Mel   Nor  
22   59   F   IgG,λ   VAD, IEV, Hd-Mel   ND  
23   65   M   IgG,κ   D   ND  
24   59   M   IgG,κ   MP, VBAP, CC5013 + D   ND  
25
 
65
 
F
 
IgG,κ
 
VAD, IEV, T-Hd-Mel, D, Bort
 
ND
 

FISH indicates fluorescence in situ hybridization; ID, idarubicin/dexamethasone; IEV, ifosfamide/epirubicin/etoposide; Hd-Mel, high-dose melphalan; ND, not determined; VAD, vincristine/Adriamycin/dexamethasone; Del, deleted; NS, nonsecretory; D, dexamethasone; Nor, normal; T-Hd-Mel, tandem high-dose melphalan; AD, Adriamycin/dexamethasone; Mel, melphalan; VCAP, vincristine/cyclophosphamide/Adriamycin/prednisone; BP, bendamustine/prednisone; Bort, bortezomib; MP, melphalan/prednisone; B, bendamustine; CC-5013: lenalidomide; Thal, thalidomide; TamD, tamoxifen/dexamethasone; VBAP, vincristine/bendamustine/Adriamycin/prednisone.

or Create an Account

Close Modal
Close Modal